{'52WeekChange': 1.0716765,
 'SandP52WeekChange': 0.0644362,
 'address1': '85 Wells Avenue',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 17.88,
 'askSize': 800,
 'averageDailyVolume10Day': 1542262,
 'averageVolume': 1884969,
 'averageVolume10days': 1542262,
 'beta': 1.50028,
 'beta3Year': None,
 'bid': 17.6,
 'bidSize': 1200,
 'bookValue': 2.273,
 'category': None,
 'circulatingSupply': None,
 'city': 'Newton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.43,
 'dayLow': 17.62,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.351,
 'enterpriseToRevenue': 18.419,
 'enterpriseValue': 1084439680,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 18.662,
 'fiftyTwoWeekHigh': 29.61,
 'fiftyTwoWeekLow': 7.55,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43798564,
 'forwardEps': -1.4,
 'forwardPE': -12.8,
 'fromCurrency': None,
 'fullTimeEmployees': 347,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.12782,
 'heldPercentInstitutions': 0.91033995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/karyopharm.com',
 'longBusinessSummary': 'Karyopharm Therapeutics Inc., a pharmaceutical '
                        'company, engages in the discovery, development, and '
                        'commercialization of various drugs directed against '
                        'nuclear export and related targets for the treatment '
                        'of cancer and other diseases. The company is '
                        'developing small molecule selective inhibitor of '
                        'nuclear export (SINE) compounds that inhibit the '
                        'nuclear export protein exportin 1. Its lead compound '
                        'is XPOVIO (selinexor) tablets for the treatment of '
                        'patients with heavily pretreated multiple myeloma. '
                        'The company develops BOSTON, which is in Phase 3 '
                        'clinical trial for the treatment of patients with '
                        'multiple myeloma; STORM, which is in Phase 2b '
                        'single-arm clinical trial for evaluating oral '
                        'selinexor in combination with standard, low-dose '
                        'dexamethasone in heavily pretreated patients, '
                        'relapsed or refractory myeloma; STOMP, which is in '
                        'Phase 1b/2 multi-arm clinical trial for the treatment '
                        'of ow-dose dexamethasone plus standard therapies, '
                        'including Velcade, Kyprolis, Revlimid, and Pomalyst '
                        'or Darzalex; and SADAL, which is in Phase 2b clinical '
                        'trial for the treatment of patients with relapsed or '
                        'refractory diffuse large B-cell lymphoma. It also '
                        'develops SEAL, which is in Phase 3 clinical trial for '
                        'the treartment of liposarcoma; SIENDO, which is in '
                        'Phase 2/3 clinical trial for treatment of endometrial '
                        'cancer; and KING, which is in Phase 2 for the '
                        'treatment of glioblastoma multiforme brain tumor. In '
                        'addition, the company has various investigational '
                        'programs in clinical or preclinical development, such '
                        'as Eltanexor (KPT-8602), KPT-9274, and Verdinexor '
                        '(KPT-335). The company has collaboration with '
                        'PROMETRIKA, LLC to conduct the first randomized '
                        'clinical trial for low-dose selinexor (XPOVIOÃ\x82), '
                        'an XPO1 inhibitor for hospitalized patients with '
                        'COVID-19; and a cooperative research and development '
                        'agreement with the National Cancer Institute for '
                        'cancer therapy evaluation program. Karyopharm '
                        'Therapeutics Inc. was founded in 2008 and is '
                        'headquartered in Newton, Massachusetts.',
 'longName': 'Karyopharm Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 1310344576,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_115373285',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -186360000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.25,
 'phone': '617 658 0600',
 'previousClose': 18.62,
 'priceHint': 2,
 'priceToBook': 7.883854,
 'priceToSalesTrailing12Months': 22.256006,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.43,
 'regularMarketDayLow': 17.62,
 'regularMarketOpen': 18.41,
 'regularMarketPreviousClose': 18.62,
 'regularMarketPrice': 18.41,
 'regularMarketVolume': 1282981,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 73121904,
 'sharesPercentSharesOut': 0.213,
 'sharesShort': 15578637,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 13856804,
 'shortName': 'Karyopharm Therapeutics Inc.',
 'shortPercentOfFloat': 0.2243,
 'shortRatio': 7,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'KPTI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.928,
 'twoHundredDayAverage': 19.066978,
 'volume': 1282981,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.karyopharm.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02459'}